Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Billing Codes · Pharmacy · Rheumatology, Oncology, Pediatrics +1 moreLow impact

MA08.028k, Abatacept (Orencia®) for Injection for Intravenous Use

Effective date
Oct 1, 2025
Identified
Jun 19, 2026

Summary

Independence Blue Cross updated Medicare Advantage policy MA08.028k effective 10/01/2025 to add ICD-10 diagnosis code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) to the covered diagnoses for Abatacept (Orencia) intravenous injection. This expands the conditions under which the drug may be considered medically necessary and covered for Medicare Advantage members.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 4 steps
01By 10/01/2025: Billing team must update diagnosis code edits in the billing system to recognize M05.A as an approved diagnosis code for claims using HCPCS code J0129 (Abatacept injection, 10 mg) under Independence Blue Cross Medicare Advantage plans.
02Ensure claims adjudication rules reflect this newly added ICD-10 code to prevent unnecessary denials.
03Update internal policy reference materials and communicate the change to coding and claims staff.
04Verify that prior authorization requirements (if any) for this indication are also updated in the system.

Codes mentioned

J0129M05.A

Original notice

MA08.028k, Abatacept (Orencia®) for Injection for Intravenous Use
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
08.00.62r, Abatacept (Orencia®) for Injection for Intravenous UseLowEffective Oct 1, 2025 · Pharmacy08.00.62s, Abatacept (Orencia®) for Injection for Intravenous UseMediumEffective Oct 5, 2026 · PharmacyMA08.028l, Abatacept (Orencia®) for Injection for Intravenous UseMediumEffective Oct 5, 2026 · PharmacyMA08.070f, Golimumab (Simponi Aria®) Intravenous (IV) InjectionMediumEffective Oct 1, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesRheumatologyOncologyPediatricsHematologyCode J0129Code M05.A

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account